Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Genitourinary tumours, prostate

LBA22 - Imaging based PCa screening among BRCA mutation carriers: Results from the first round of screening


18 Sep 2020


Mini Oral - Genitourinary tumours, prostate


David Margel


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


D. Margel1, Y. Ber1, N. Segal1, O. Benjaminov2, S. Tamir3, M. Yakimov4, I. Kedar5, S. Sela1, R. Ozalvo1, L. Shavit-Grievink1, D. Kedar1, J. Baniel1, E. Rosenbaum6

Author affiliations

  • 1 Urology, Rabin Medical Center, 49100 - Petah Tikva/IL
  • 2 Imaging, Shaare Zedek Medical Center, Jerusalem/IL
  • 3 Imaging, Rabin Medical Center, 49100 - Petah Tikva/IL
  • 4 Pathology, Rabin Medical Center, 49100 - Petah Tikva/IL
  • 5 Genetics, Rabin Medical Center, 49100 - Petah Tikva/IL
  • 6 Davidoff Cancer Center, Rabin Medical Center, 49100 - Petah Tikva/IL


Login to access the resources on OncologyPRO.

Abstract LBA22


Male-carriers of BRCA1/2 gene mutations have an increased risk of prostate cancer (PCa) with a more aggressive phenotype. Current screening guidelines suggest the use of PSA only among BRCA2 carriers. Female carriers have extensive guidelines that include imaging. Our objective was to test the prevalence of PCa among BRCA carriers and examine screening strategies, using PSA and multiparametric magnetic resonance imaging (mpMRI).


We recruited men aged 40–70 with BRCA1/2 germline mutations and no prior history of prostate biopsy. All men underwent an initial round of screening which included PSA, and prostate mpMRI. PSA was considered elevated using an age stratified threshold of ≥1ng/mL for 40-50Y, ≥2ng/mL for 50-60Y, and 2.5ng/mL for 60-70Y. Men with elevated PSA and/or suspicious lesion on mpMRI were offered a biopsy. PSA levels, MRI findings, PCa incidence, and tumor characteristics were evaluated. Decision curve analysis was used to compare screening strategies.


We recruited 188 men (108 BRCA1, 80 BRCA2), mean age 54Y (±9.8). One hundred and ten (57%) had either elevated age-stratified PSA (75; 40%), a suspicious MRI lesion (67; 36%), or both (32; 17%). Of these, 92 (85%) agreed to agreed to a biopsy. Sixteen (8.5%) were diagnosed with PCa; 44% of tumors were classified as intermediate or high risk. mpMRI based screening missed only one of the cancers (6%), while age stratified PSA would have missed five (31%). Decision curve analysis showed that mpMRI screening regardless of PSA had the highest net benefit for PCa diagnosis, especially among men younger than 55Y. We found no difference in the risk of PCa between BRCA1 and BRCA2 (8.3% vs. 8.7%, p=0.91). Table: LBA22

Screening Strategy Biopsies avoided n, (%) Cancer detected n, (%) Cancer missed n, (%) Negative predictive value%, (95%CI) Positive predictivevalue%, (95%CI)
PSA>3 67 (73%) 5 (31%) 11 (69%) 83.6% (78.1-87.9) 20% (9.9-36.2)
Elevated Age-stratified PSA 32 (35%) 5 (31%) 11 (69%) 84.4% (71.1-92.2) 18.3% (13.4-24.5)
PI-RADS≥3 29 (32%) 15 (94%) 1 (6%) 96.6% (80.4-99.5) 23.8% (20.2-27.9)
PSA>3 AND PI-RADS≥3 74 (80%) 9 (56%) 7 (44%) 90.6% (84.5-94.4) 50% (32.1-67.9)
Elevated Age-stratified PSA AND PI-RADS≥3 61 (66%) 10 (63%) 6 (27%) 90% (82.5-94.5) 31.3% (21.3-43.3)


PCa is prevalent among BRCA carriers. Age may affect screening strategy for PCa in this population. Young carriers could benefit from initial MRI screening. BRCA carriers older than 55Y should use PSA and referred to mpMRI if elevated.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

David Margel.


American Society of Clinical Oncology (ASCO).


D. Margel: Research grant/Funding (self), Career Development Award 2015: ASCO. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings